| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
AZD8797 (AZD-8797) is a novel, selective, orally bioavailable and allosteric non-competitive modulator of the human CX3CR1 receptor with potential anti-Inflammatory and immunomodulatory activity. It irritates CX3CR1 and CXCR2, with corresponding Ki values of 3.9 and 2800 nM. AZD8797 inhibited the natural ligand fractalkine (CX3CL1) in a flow adhesion assay using IC50 values of 300 and 6 nM, respectively, in human whole blood (hWB) and a B-lymphocyte cell line. In an assay for [(35)S]GTPηS (guanosine 5'-[γ-thio]triphosphate) accumulation, AZD8797 also inhibited G-protein activation. By contrast, AZD8797 agonism was found to be weakly Gαi-dependent through dynamic mass redistribution (DMR) experiments. Furthermore, in an β-arrestin recruitment assay, AZD8797 positively modulated the CX3CL1 response at sub-micromolar concentrations. AZD8797 decreased the maximum binding of (125)I-CX3CL1 in equilibrium saturation binding experiments while having no effect on Kd. Kinetic studies that determined the kon and koff of AZD8797 showed that this was a genuine non-competitive mechanism rather than an artifact of irreversible or insurmountable binding. Ultimately, we demonstrate that GTPγS and AZD8797 both raise the rate at which CX3CL1 separates from CX3CR1 in a comparable way, suggesting a link between AZD8797 and the G-protein bound to CX3CR1. All together, these findings demonstrate that AZD8797 functions as a non-competitive allosteric modulator of CX3CL1, binding CX3CR1 and causing biased effects on G-protein signaling and β-arrestin acquisition.
| Targets |
CX3CR1 ( Ki = 3.9 nM ); 125I-IL-8-CXCR2 ( Ki = 2800 nM )
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Enzyme Assay |
In a MicroWell 96-well plate, CHO-hCX3CR1 membranes are incubated in 50 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 10 μM GDP, and 0.01% gelatin along with varying concentrations of AZD8797. Next, EC80 of CX3CL1 and 0.56 μCi/mL [35S]GTPηS are added. After one hour of incubation at 30°C, the plate is vacuum-filtered to a Printed Filtermat B to separate the bound and unbound [35S]GTPγS. Regardless of the AZD8797 concentration, the various AZD8797 concentrations are obtained by stepwise dilution in DMSO, which results in a final DMSO concentration of 1% in all wells following the addition of assay buffer.
|
|
| Cell Assay |
AZD8797 inhibits the natural ligand fractalkine (CX3CL1) in a flow adhesion assay using IC50 values of 300 and 6 nM, respectively, in human whole blood (hWB) and a B-lymphocyte cell line. Additionally, AZD8797 inhibits G-protein activation in an assay for [35S]GTPγS accumulation. In an β-arrestin recruitment assay, AZD8797 at sub-micromolar concentrations positively modulates the CX3CL1 response. AZD8797 lowers the maximal binding of 125I-CX3CL1 in equilibrium saturation binding experiments while having no effect on Kd. AZD8797 exhibits high affinity and selectivity when binding to CX3CR1 in both humans and rats (Ki of hCX3CR1, 4 nM, and Ki of rCX3CR1, 7 nM, respectively). AZD8797 is a very strong inhibitor of human CX3CR1 (10 nM), as evidenced by the equilibrium dissociation constant, KB. Rat CX3CR1 has a potency of 29 nM, which is three times lower than mouse CX3CR1, which has an even smaller potency of 54 nM.
|
|
| Animal Protocol |
|
|
| References |
|
| Molecular Formula |
C19H25N5OS2
|
|
|---|---|---|
| Molecular Weight |
403.56
|
|
| Exact Mass |
403.15
|
|
| Elemental Analysis |
C, 56.55; H, 6.24; N, 17.35; O, 3.96; S, 15.89
|
|
| CAS # |
911715-90-7
|
|
| Related CAS # |
|
|
| PubChem CID |
11965767
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
651.1±65.0 °C at 760 mmHg
|
|
| Flash Point |
347.6±34.3 °C
|
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
|
| Index of Refraction |
1.669
|
|
| LogP |
4.6
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
8
|
|
| Rotatable Bond Count |
8
|
|
| Heavy Atom Count |
27
|
|
| Complexity |
452
|
|
| Defined Atom Stereocenter Count |
2
|
|
| SMILES |
N(C1N=C(S[C@H](C2C=CC=CC=2)C)N=C2N=C(SC=12)N)[C@@H](CO)CC(C)C
|
|
| InChi Key |
ZMQSLMZOWVGBSM-GXTWGEPZSA-N
|
|
| InChi Code |
InChI=1S/C19H25N5OS2/c1-11(2)9-14(10-25)21-16-15-17(22-18(20)27-15)24-19(23-16)26-12(3)13-7-5-4-6-8-13/h4-8,11-12,14,25H,9-10H2,1-3H3,(H3,20,21,22,23,24)/t12-,14+/m0/s1
|
|
| Chemical Name |
(2R)-2-[[2-amino-5-[(1S)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5 mg/mL (12.39 mM) in 20% HP-β-CD in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4779 mL | 12.3897 mL | 24.7795 mL | |
| 5 mM | 0.4956 mL | 2.4779 mL | 4.9559 mL | |
| 10 mM | 0.2478 mL | 1.2390 mL | 2.4779 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 The CX3CR1 inhibitor AZD8797 blocks MOG-EAE in DA rats.Proc Natl Acad Sci U S A.2014 Apr 8;111(14):5409-14. |
|---|
 AZD8797 treatment in EAE reduces TSPO binding, a clinically relevant marker for microglia activation.Proc Natl Acad Sci U S A.2014 Apr 8;111(14):5409-14. |
 AZD8797 treatment in rats with established EAE inhibits development of relapses and all histopathological manifestations of the disease.Proc Natl Acad Sci U S A.2014 Apr 8;111(14):5409-14. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA